KYNB Stock Forecast: Kyntra Bio, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.56
−14.75% on the day

The median 12-month analyst price target for Kyntra Bio, Inc. is $24. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 41 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$7.4M
Ticker Nerd rank
41/ 100
Median analyst target
$24
Analysts covering
5
Revenue−$1.5M−209.3% y/y
Operating income−$17.6M
Net income$12.0M
Free cash flow−$4.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−54.7%
1M
−70.5%
YTD
−82.2%
1Y
−81.2%
From 52W high
−84.5%
From 52W low
0.0%
$2
$10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Kyntra Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
41/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
94
Revisions
82
Quality
35
Value
28
Volatility
23
Growth
19
Accruals
17
Momentum
12

Issuance (94): The share count has been shrinking and the company is not leaning on new borrowing.

Momentum (12): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

KYNB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KYNB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26KYNBHigh $35Median $24Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4
Buy
1
Hold
0
Sell
$8
Low
$24
Median
$35
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 7 moved it down.

DateFirmActionRatingTarget
17 Nov 2026HC Wainwright & Co.MaintainsBuy$43 → $18
17 Nov 2026Lake StreetMaintainsBuy$41 → $8.00
17 Nov 2026OppenheimerMaintainsOutperform$35 → $30
13 Oct 2026Maxim GroupInitiatesBuy$35
17 Sept 2026Lake StreetInitiatesBuy$41
1 Sept 2026HC Wainwright & Co.ReiteratesBuy$43
7 July 2026OppenheimerInitiatesOutperform$35
9 June 2026Rodman & RenshawInitiatesBuy—
24 Sept 2025HC Wainwright & Co.ReiteratesBuy—
7 Aug 2025HC Wainwright & Co.MaintainsBuy—
13 May 2025HC Wainwright & Co.ReiteratesBuy$10
18 Mar 2025HC Wainwright & Co.ReiteratesBuy$10
20 Feb 2025HC Wainwright & Co.ReiteratesBuy$10
8 Aug 2023B of A SecuritiesDowngradeUnderperform$4.00 → $2.00
27 June 2023Goldman SachsMaintainsSell$16 → $2.00
27 June 2023Raymond JamesDowngradeMarket Perform—
26 June 2023B of A SecuritiesDowngradeNeutral$29 → $4.00
26 June 2023Raymond JamesDowngradeMarket Perform—
26 June 2023StifelDowngradeHold$28 → $11
26 June 2023William BlairDowngradeMarket Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for KYNB.

Market Radar

This page is one stock. Monday covers all of them.

KYNB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

KYNB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Kyntra Bio, Inc. returned −81.2% against +6.9% for the S&P 500, dividends included.

KYNB vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26KYNBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KYNB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.4×

Cheaper than 58% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−38.9%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kyntra Bio, Inc. has a market value of $7.4M.

  • Revenue in the twelve months to 30 June 2026: $4.6M. The latest quarter shrank 209.3% year on year.

  • Net income over the same four quarters: $183.2M, a 3967.8% net margin.

  • Diluted earnings per share, trailing twelve months: $45.30.

  • Free cash flow in the twelve months to 30 June 2026: −$38.1M.

  • Shares outstanding: 4.0M.

  • Kyntra Bio, Inc. employs 34 people — $136K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

KYNB and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KYNBKyntra Bio, Inc.$7.4M41
ACXPAcurx Pharmaceuticals, Inc.$6.3M18
FBLGFibroBiologics, Inc.$6.3M64
CNSYCerenome, Inc.$6.2M13
GTBPGT Biopharma, Inc.$6.1M13
ENVBEnveric Biosciences, Inc.$6.0M16
MTVAMetaVia, Inc.$6.7M10

Take a look at KYNB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Kyntra Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about KYNB

What is the KYNB stock price forecast for 2026-2027?

The median 12-month analyst price target for Kyntra Bio, Inc. is $24, with estimates ranging from $8 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KYNB stock a buy right now?

Of the 5 analysts covering Kyntra Bio, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kyntra Bio, Inc. 41 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KYNB?

As at 21 Nov 2026, Kyntra Bio, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Issuance (94 of 100).

Will KYNB stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts is $24, and Ticker Nerd's factor model ranks Kyntra Bio, Inc. 41 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KYNB stock forecast for 2030?

No analyst covering Kyntra Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KYNB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $35 over the next 12 months.

How has KYNB stock performed over the past year?

Kyntra Bio, Inc. returned -81.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kyntra Bio, Inc. do?

Kyntra Bio, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for serious unmet medical needs. Kyntra Bio’s current pipeline centers on oncology and anemia, including FG-3246, an antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer and other cancers, as well as roxadustat, a small-molecule HIF-PH inhibitor being developed for anemia-related indications.

Company

About Kyntra Bio, Inc.

Kyntra Bio, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for serious unmet medical needs. Kyntra Bio’s current pipeline centers on oncology and anemia, including FG-3246, an antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer and other cancers, as well as roxadustat, a small-molecule HIF-PH inhibitor being developed for anemia-related indications. The company also works in fibrotic disease biology through its research on hypoxia-inducible factor and connective tissue growth factor pathways. Headquartered in San Francisco, California, Kyntra Bio serves the broader life sciences market by advancing treatments intended for patients with cancer, blood disorders, and other severe diseases.

CEO Mr. Thane Wettig · 34 employees · United States · https://www.kyntrabio.com